Survodutide
InvestigationalAlso known as: BI 456906, BI-456906, ZP6590
A dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim/Zealand Pharma, currently in Phase 3 trials for obesity and MASH. Phase 2 data show 18.7% weight loss and 83% MASH resolution, with unique liver-targeting benefits from glucagon receptor agonism.
Research Statistics
Dual GLP-1/glucagon receptor agonist (BI 456906) in Phase 3 for obesity and MASH. Phase 2 shows 18.7% weight loss, 83% MASH resolution. Primarily European-led trials (Boehringer Ingelheim) with some US sites. GLP-1 and glucagon receptor mechanisms are individually well-established; dual agonism rationale is solid.
Research Dossier
Overview
What is Survodutide and what does the research say?
Mechanism of Action
Survodutide is a dual GLP-1/glucagon receptor agonist with Phase 2 clinical trial evidence supporting its mechanisms in humans.
How It Works (Simplified)
Survodutide acts as a “dual signal” metabolic regulator through complementary pathways:
GLP-1 receptor activation in the brain promotes satiety, reducing food intake and cravings through hypothalamic signaling.
Glucagon receptor activation directly targets the liver (which lacks GLP-1 receptors), promoting hepatic lipid oxidation and reducing fatty liver.
GLP-1 enhances insulin secretion while glucagon typically raises glucose - the dual action maintains glycemic control with net improvement.
Glucagon receptor activation in brown adipose tissue may increase energy expenditure, adding caloric burn beyond appetite reduction.
Scientific Pathways
GLP-1 Receptor Pathway (Satiety & Insulin)
Survodutide → GLP-1R activation → Hypothalamus POMC/NPY modulation → Reduced appetite
→ Pancreatic beta cells → Glucose-dependent insulin
→ GI tract → Delayed gastric emptyingGlucagon Receptor Pathway (Liver & Thermogenesis)
Survodutide → GCGR activation → Liver (high GCGR, NO GLP-1R) → Hepatic lipid oxidation
↓
Reduced steatosis, MASH resolution
→ Brown adipose tissue → Increased thermogenesisKey Research: Sanyal AJ et al. (NEJM, 2024) demonstrated 83% MASH resolution with 6.0mg dose, the highest rate reported for any drug in Phase 2. PMID:38507727
Important Limitations
- Phase 3 trials ongoing; not yet FDA approved for any indication
- Long-term safety beyond 48 weeks not established
- No head-to-head trials vs semaglutide or tirzepatide
- Cardiovascular outcomes unknown (CVOT results expected 2029+)
- Cross-trial comparisons to other agents are inherently unreliable
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Dose escalation phase. Common GI side effects (nausea, reduced appetite) typically emerge. Early weight loss primarily from reduced caloric intake via GLP-1 pathway.
Continued dose escalation toward target dose. Weight loss accelerates. GI tolerability typically improves. Early metabolic improvements in glucose and liver enzymes.
Target dose achieved. Steady-state drug levels (~4-5 weeks after stable dosing). Significant weight loss observable. Liver fat reduction becomes measurable.
Continued weight loss with trajectory not yet plateaued at 46 weeks. In MASH patients, histological improvements (resolution, fibrosis) documented at 48 weeks.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Survodutide product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Survodutide with other peptides. Based on published research and mechanistic considerations.
TB-500
CompatibleNon-overlapping mechanisms. TB-500 focuses on tissue repair while survodutide targets metabolic pathways. No known contraindications.
GHK-Cu
CompatibleDifferent mechanisms of action. GHK-Cu targets copper-mediated signaling while survodutide affects GLP-1/glucagon pathways. No interaction concerns.
BPC-157
CautionBPC-157 affects GI function and survodutide slows gastric emptying. Unclear if effects interact; monitor GI symptoms if combined.
Semaglutide
AvoidBoth are GLP-1 receptor agonists. Combining would result in overlapping mechanisms with increased risk of severe GI adverse events and no established benefit. Contraindicated.
Tirzepatide
AvoidBoth target GLP-1 receptor pathway. Combination would duplicate mechanisms and significantly increase adverse event risk without demonstrated benefit.
Retatrutide
AvoidRetatrutide is a triple agonist (GLP-1/GIP/glucagon) that fully overlaps with survodutide's dual mechanism. Combining would be redundant with compounded risks.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Survodutide
Survodutide Calculators
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.